MX2014003898A - Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos. - Google Patents

Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos.

Info

Publication number
MX2014003898A
MX2014003898A MX2014003898A MX2014003898A MX2014003898A MX 2014003898 A MX2014003898 A MX 2014003898A MX 2014003898 A MX2014003898 A MX 2014003898A MX 2014003898 A MX2014003898 A MX 2014003898A MX 2014003898 A MX2014003898 A MX 2014003898A
Authority
MX
Mexico
Prior art keywords
pain
methanone
indol
thiazole
fluorophenyl
Prior art date
Application number
MX2014003898A
Other languages
English (en)
Other versions
MX342140B (es
Inventor
Kenneth M Wells
Derek A Beauchamp
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2014003898A publication Critical patent/MX2014003898A/es
Publication of MX342140B publication Critical patent/MX342140B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una sal clorhidrato cristalina de (1-(4-fluorofenil)-1H-indol-5-iI)(3-(4-(tiazol-2-carbonil)piper azin-1-iI)azetidin-1-il)metanona, (ver Fórmula) a métodos para hacer dicha sal, composiciones farmacéuticas que contienen dicha sal, y al uso de dicha sal en el tratamiento del dolor y de enfermedades que causan dicho dolor, y trastornos metabólicos, como obesidad, hiperfagia, y diabetes.
MX2014003898A 2011-09-30 2012-09-27 Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos. MX342140B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541281P 2011-09-30 2011-09-30
PCT/US2012/057461 WO2013049287A1 (en) 2011-09-30 2012-09-27 Crystalline hydrochloride salt of (1- (4 -fluorophenyl) - 1h - indol - 5 - yl) - (3- (4- (thiazole - 2 - carbonyl) piperazin- 1 - yl) az etidin- 1 -yl) methanone and its use in the treatment of pain and metabolic disorders

Publications (2)

Publication Number Publication Date
MX2014003898A true MX2014003898A (es) 2014-12-05
MX342140B MX342140B (es) 2016-09-14

Family

ID=47046853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003898A MX342140B (es) 2011-09-30 2012-09-27 Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos.

Country Status (11)

Country Link
US (1) US8835417B2 (es)
EP (1) EP2760861A1 (es)
JP (1) JP2014528427A (es)
KR (1) KR20140072897A (es)
CN (1) CN104271573A (es)
AR (1) AR088198A1 (es)
CA (1) CA2849779A1 (es)
IN (1) IN2014DN02984A (es)
MX (1) MX342140B (es)
TW (1) TW201329073A (es)
WO (1) WO2013049287A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US8106208B2 (en) * 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
FR2915198B1 (fr) * 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CN102459255A (zh) * 2009-04-22 2012-05-16 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺

Also Published As

Publication number Publication date
US20130085279A1 (en) 2013-04-04
CN104271573A (zh) 2015-01-07
WO2013049287A1 (en) 2013-04-04
US8835417B2 (en) 2014-09-16
TW201329073A (zh) 2013-07-16
KR20140072897A (ko) 2014-06-13
EP2760861A1 (en) 2014-08-06
AR088198A1 (es) 2014-05-14
CA2849779A1 (en) 2013-04-04
JP2014528427A (ja) 2014-10-27
IN2014DN02984A (es) 2015-05-15
MX342140B (es) 2016-09-14

Similar Documents

Publication Publication Date Title
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
MY156795A (en) Ip receptor agonist heterocyclic compounds
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
TW200616953A (en) Indole, indazole or indoline derivatives
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
PL3290414T3 (pl) Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
NZ604379A (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
MY160018A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
HK1214822A1 (zh) 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
MX365108B (es) Derivados piperidina para agonista gpr119.
TN2012000531A1 (en) Substituted heterocyclyl benzyl pyrazoles, and use thereof
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
NZ727188A (en) Aldosterone synthase inhibitors
MY180310A (en) Method of treating disease by auricular anesthesia of cranial nerves

Legal Events

Date Code Title Description
FG Grant or registration